4Filing Date: Jul 7, 2026
Vertex (VRTX)
Statement of Changes in Beneficial Ownership
View SEC Filing
ACC: 0000875320-26-000243
Total Value$799.8K
Trades1
Insiders1
Transaction Details
McKechnie Duncan
EVP, Chief Commercial Officer·Direct
Sell · Dispose
Common Stock
Shares-1.54K
Price$519.00
Total Value$799.8K
Shares Owned After11.00K
Transaction DateJul 2, 2026
10b5-1
Footnotes ▸
Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.
Post-Transaction Holdings
McKechnie Duncan · EVP, Chief Commercial Officer
| Security | Shares | Change |
|---|---|---|
| Common Stock | 11.00K | -1.54K (-12.29%) |
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership ===
Document Type: 4
Period of Report: 2026-07-02
10b5-1 Pre-arranged Plan: Yes
--- Issuer ---
Name: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
--- Reporting Owner ---
Name: McKechnie Duncan
CIK: 0002062139
Role: Officer (EVP, Chief Commercial Officer)
--- Non-Derivative Transactions ---
[Transaction #1]
Security: Common Stock
Date: 2026-07-02 | Code: S (Open market sale)
Shares: -1,541 | Price: $519.00
Total Value: $799,779.00
Shares Owned After: 11,001 | Ownership: D (Direct)
Footnotes:
[F1] Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.
--- Footnotes (Complete Index) ---
F1: Transaction made pursuant to Mr. McKechnie's company approved trading plan under Rule 10b5-1, which was entered into on 11/25/2025.
--- Signature ---
/s/ /s/ Christiana Stevenson, Attorney-in-Fact (2026-07-07)